Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro

BMC Cancer

Brian I Carr¹  Aldo Cavallini¹  Rosalba D’Alessandro¹  Maria Grazia Refolo¹  Catia Lippolis¹  Antonio Mazzocca²  Caterina Messa¹ 

[1] Laboratory of biochemistry and tumor biology, National Institute for Digestive Diseases, IRCCS ‘Saverio de Bellis’, via Turi 27, 70013 Castellana Grotte, BA, Italy

[2] Department of Emergency and Organ Transplantation, Section of Internal Medicine, University of Bari, piazza G. Cesare, 70100 Bari, Italy

关键词: AFP;    Invasion;    Migration;    Growth;    HCC;    Platelets;   

Others  :  859113
DOI  :  10.1186/1471-2407-14-43

 received in 2013-09-13, accepted in 2014-01-21,  发布年份 2014

【 摘 要 】

Background

Thrombocytopenia has been reported to be associated with small size HCCs, and thrombocytosis to be associated with large size HCCs. The aim was to examine the effects of platelets in relation to HCC cell growth.

Methods

The effects of time-expired pooled normal human platelets were examined on human HCC cell line growth and invasion.

Results

Blood platelet numbers increased with increasing HCC tumor size and portal vein invasion. Platelet extracts enhanced cell growth in 4 human HCC cell lines, as well as cell migration, medium AFP levels and decreased apoptosis. Cell invasion was significantly enhanced, using a Matrigel-coated trans-well membrane and3D (Real-Time Imaging) invasion assay. Western blots showed that platelets caused enhanced phospho-ERK and phospho–JNK signaling and anti-apoptotic effect with increase of Bcl-xL (anti-apoptotic marker) and decrease of Bid (pro-apoptotic marker) levels. Their growth effects were blocked by a JNK inhibitor.

Conclusions

Platelets stimulated growth and invasion of several HCC cell lines in vitro, suggesting that platelets or platelet growth factors could be a potential pharmacological target.

【 授权许可】

   
2014 Carr et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Ries I: Zurpathologischen Anatomie des Blutes. Arch Anat Physiol Wissensch Med 1872, 39:237-249.
• [2]Leslie M: Cell biology: beyond clotting: the powers of platelets. Science 2010, 328:562-564.
• [3]Levin J, Conley CL: Thrombocytosis associated with malignant disease. Arch Intern Med 1964, 114:497-500.
• [4]Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN: Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012, 366:610-618.
• [5]Borsig L: The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther 2008, 8:1247-1255.
• [6]Labelle M, Begum S, Hynes RO: Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011, 20:576-590.
• [7]Buergy D, Wenz F, Groden C, Brockmann MA: Tumor-platelet interaction in solid tumors. Int J Cancer 2012, 130:2747-2760.
• [8]Matsuo R, Nakano Y, Ohkohchi N: Platelet administration via the portal vein promotes liver regeneration in rats after 70% hepatectomy. Ann Surg 2011, 253:759-763.
• [9]Matsuo R, Ohkohchi N, Murata S, Ikeda O, Nakano Y, Watanabe M, Hisakura K, Myronovych A, Kubota T, Narimatsu H, Ozaki M: Platelets strongly induce hepatocyte proliferation with IGF-1and HGF in vitro. J Surg Res 2008, 145:279-286.
• [10]Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, Gachet C, Bader M, Clavien PA: Platelet-derived serotonin mediates liver regeneration. Science 2006, 312:104-107.
• [11]Carr BI, Guerra V, Pancoska P: Thrombocytopenia in relation to tumor size in patients with hepatocellularcarcinoma. Oncology 2012, 83:339-345.
• [12]Carr BI, Guerra V: Features of massive hepatocellular carcinomas. Eur J Gastroenterol Hepatol 2013. July 16, Epub. PMID 23863262
• [13]Carr BI, Guerra V: Thrombocytosis and hepatocellular carcinoma. Dig Dis Sci 2013, 58:1790-1796.
• [14]Carr BI, Cavallini A, Lippolis C, D'Alessandro R, Messa C, Refolo MG, Tafaro A: Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol 2013, 228:292-297.
• [15]Mazzocca A, Coppari R, De Franco R, Cho JY, Libermann TA, Pinzani M, Toker A: A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res 2005, 65:4728-4738.
• [16]Holmes CE, Levis JE, Ornstein DL: Activated platelets enhance ovarian cancer cell invasion in acellular model of metastasis. Clin Exp Metastasis 2009, 26:653-661.
• [17]Steller EJ, Raats DA, Koster J, Rutten B, Govaert KM, Emmink BL, Snoeren N, van Hooff SR, Holstege FC, Maas C, Borel Rinkes IH, Kranenburg O: PDGFRB promotes liver metastasis Formation of mesenchymal-like colorectal tumor cells. Neoplasia 2013, 15:204-207.
• [18]Bambace NM, Holmes CE: The platelet contribution to cancer progression. J Thromb Hemostat 2011, 9:237-249.
• [19]Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M: The platelet-cancer loop. Eur J Intern Med 2013, 24:393-400.
• [20]Kawasaki T, Murata S, Takahashi K, Nozaki R, Ohshiro Y, Ikeda N, Pak S, Myronovych A, Hisakura K, Fukunaga K, Oda T, Sasaki R, Ohkohchi N: Activation of human liver sinusoidal endothelial cell by human platelets induces hepatocyte proliferation. J Hepatol 2010, 53:648-654.
• [21]Nowatari T, Fukunaga K, Ohkohchi N: Regulation of signal transduction and role of platelets in liver regeneration. Int J Hepatol 2012, 2012:542479.
• [22]Awuah PK, Nejak-Bowen KN, Monga SP: Role and regulation of PDGFRα signaling in liver development and regeneration. Am J Path 2013, 182:1648-1658.
• [23]Yu Y, Zhou XD, Liu YK, Ren N, Chen J, Zhao Y: Platelets promote the adhesion of human hepatoma cells with a highly metastatic potential to extracellular matrix protein: involvement of platelet P-selectin and GP IIb-IIa. J Cancer Res Clin Oncol 2000, 128:283-287.
• [24]Ferroni P, Spila A, D’Alessandro R, Martini F, Iacovone F, Ettorre GM, Vennarecci G, Santoro R, Puoti C, Guadagni F: Platelet activation and vascular endothelial growth factor165 release in hepatocellular carcinoma. Clin Chim Acta 2011, 412:450-454.
• [25]Zhou J, Tang ZY, Fan J, Wu ZQ, Li XM, Liu YK, Liu F, Sun HC, Ye SL: Expression of platelet-derived endothelial cell growth factor and vascular endothelial cell growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J Cancer Res Clin Oncol 2000, 126:57-61.
• [26]Yang ZF, Ho DW, Lau CK, Tam KH, Lam CT, Poon RT, Fan ST: Platelet activation during tumor development, the potential roleof BDNF-Trk Bautocrine loop. Biochem Biophys Res Commun 2006, 346:981-985.
• [27]Okada H, Honda M, Campbell JS, Sakai Y, Yamashita T, Takebuchi Y, Hada K, Shirasaki T, Takabatake R, Nakamura M, Sunagozaka H, Tanaka T, Fausto N, Kaneko S: Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development. Cancer Res 2012, 72:4459-4471.
• [28]Liang C, Chen W, Zhi X: Serotonin promotes the proliferation of serum-deprived hepatocellularcarcinoma cells via upregulation of FOXO3a. Mol Cancer 2013, 9:12-14.
• [29]French DM, Lin BC, Wang M, Adams C, Shek T, Hötzel K, Bolon B, Ferrando R, Blackmore C, Schroeder K, Rodriguez LA, Hristopoulos M, Venook R, Ashkenazi A, Desnoyers LR: Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One 2012, 7:e36713.
• [30]Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, Mingozzi F, Esposito A, Ruggeri ZM, Chisari FV, Iannacone M, Guidotti LG: Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA 2012, 109:E2165-E2172.
• [31]Leng T, Liu N, Dai Y: Dissection of DEN-induced platelet proteome changes reveals the progressively dys-regulated pathways indicative of hepatocarcinogenesis. J Proteome Res 2010, 9:6207-6219.
• [32]Amable PR, Carias RB, Teixeira MV, da Cruz Pacheco I, Amaral RJ C d, Granjeiro JM, Borojevic R: Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther 2013, 4:67. BioMed Central Full Text
• [33]Dhillon RS, Schwarz EM, Maloney MD: Platelet-rich plasma therapy-future or trend? Arthritis Res Ther 2012, 14:219. BioMed Central Full Text
• [34]Abiru S, Nakao K, Ichikawa T, Migita K, Shigeno M, Sakamoto M, Ishikawa H, Hamasaki K, Nakata K, Eguchi K: Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology 2002, 35:1117-1124.
• [35]Hossain MA, Kim DH, Jang JY, Kang YJ, Yoon JH, Moon JO, Chung HY, Kim GY, Choi YH, Copple BL, Kim ND: Aspirin induces apoptosis in vitro and inhibits tumorgrowth of human hepatocellular carcinoma cells in a nude mouse xenograft model. Int J Oncol 2012, 40:1298-1304.
• [36]Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z: Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012, 379:1591-1601.
• [37]Algra AM, Rothwell PM: Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012, 13:518-527.
• [38]Gasic GJ, Gasic TB, Stewart CC: Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968, 61:46-52.
• [39]Futakuchi M, Ogawa K, Sano M, Tamano S, Takeshita F, Shirai T: Suppression of lung metastasis by aspirin but not byindomethacin in an in vivo model of chemically induced hepatocarcinogenesis. Jpn J Cancer Res 2002, 93:1175-1181.
• [40]Park HB, Yang JH, Chung KH: Characterization of the cytokine profile of platelet rich plasma (PRP) and PRP-induced cell proliferation and migration: upregulation of matrix metalloprotein-1 and -9 in HaCaT cells. Korean J Hematol 2011, 46:265-273.
• [41]Dahesvsky O, Varon D, Brill A: Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. Int J Cancer 2009, 124:1773-1777.